RAPT Therapeutics, Inc.’s Initial Public Offering

Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc.

RAPT Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol “RAPT”.

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as underwriters on the deal.

The Davis Polk corporate team included partner Bruce K. Dallas (Picture) and associates Scott A. Blumenkranz and Jonathan Bye. Partner Rachel D. Kleinberg provided tax advice. Partner David R. Bauer and associates Mikaela Dealissia and Jennifer Leather provided intellectual property and technology advice. Counsel Gregory D. Hughes provided executive compensation advice. Associate Sijia Cai provided 1940 Act advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Jonathan Bye – Davis Polk & Wardwell; Sijia Cai – Davis Polk & Wardwell; Bruce Dallas – Davis Polk & Wardwell; Mikaela Dealissia – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Gregory Hughes – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Jennifer Leather – Davis Polk & Wardwell; Scott Blumenkranz – Wilson Sonsini Goodrich & Rosati;

Law Firms: Davis Polk & Wardwell; Wilson Sonsini Goodrich & Rosati;

Clients: BMO Capital Markets; UBS Investment Bank; Wells Fargo Securities;

Author: Ambrogio Visconti